Gao 2012.

Methods	Randomised clinical trial.
Participants	Country: China. Number randomised: 79. Post‐randomisation dropouts: not stated. Revised sample size: 79. Mean age: 53 years. Females: 77 (97.5%). Symptomatic participants: not stated. AMA positive: not stated. Responders: not stated. Mean follow‐up period (for all groups): not stated. Inclusion criteria Symptom status: not stated. AMA status: not stated. Response status: not stated. Other inclusion criteria Only people with Sjogren's syndrome were included. Exclusion criteria People with decompensated cirrhosis. Aged > 70 years. Other autoimmune diseases.
Interventions	Participants were randomly assigned to 3 groups. Group 1: UDCA (moderate) (n = 29). Further details: UDCA: 13 mg/kg/day to 15 mg/kg/day; duration: not stated. Group 2: UDCA (moderate) + glucocorticosteroids (n = 37). Further details: UDCA: 13 mg/kg/day to 15 mg/kg/day; duration: not stated + prednisolone: 7.5 mg/day; duration: not stated. Group 3: UDCA (moderate) + azathioprine (n = 13). Further details: UDCA: 13 mg/kg/day to 15 mg/kg/day; duration: not stated + azathioprine: 1 mg/kg/day; duration: not stated.
Outcomes	Adverse events, decompensated liver disease.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: information not available.
Allocation concealment (selection bias)	Unclear risk	Comment: information not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: information not available.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: information not available.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: information not available.
Selective reporting (reporting bias)	High risk	Comment: mortality not reported.
For‐profit bias	Unclear risk	Comment: information not available.
Other bias	Low risk	Comment: no other source of bias.